Literature DB >> 33925214

Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.

Alejandro Olivares-Hernández1,2, Luis Figuero-Pérez1,2, Eduardo Terán-Brage1,2, Álvaro López-Gutiérrez1,2, Álvaro Tamayo Velasco3, Rogelio González Sarmiento2,4, Juan Jesús Cruz-Hernández1,2,4, José Pablo Miramontes-González5,6.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.

Entities:  

Keywords:  haematological malignancies; immune checkpoint inhibitors (ICIs); immune resistance; myeloid-derived suppressor cells (MDSCs)

Year:  2021        PMID： 33925214     DOI： 10.3390/jcm10091919

Source DB:  PubMed          Journal:  J Clin Med        ISSN： 2077-0383            Impact factor:   4.241


  160 in total

1.  Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.

Authors:  Chongyang Wu; Xiangyang Wu; Xiaoni Zhang; Ye Chai; Qi Guo; Lijuan Li; Lingling Yue; Jun Bai; Zhiping Wang; Liansheng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.

Authors:  Guang-Tao Yu; Liang Mao; Lei Wu; Wei-Wei Deng; Lin-Lin Bu; Jian-Feng Liu; Lei Chen; Lei-Lei Yang; Hao Wu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Cell Mol Life Sci       Date:  2018-06-28       Impact factor: 9.261

3.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Authors:  Ashley Orillion; Ayumi Hashimoto; Nur Damayanti; Li Shen; Remi Adelaiye-Ogala; Sreevani Arisa; Sreenivasulu Chintala; Peter Ordentlich; Chingai Kao; Bennett Elzey; Dmitry Gabrilovich; Roberto Pili
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

Review 4.  Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer.

Authors:  Su-Myeong Park; Je-In Youn
Journal:  Arch Pharm Res       Date:  2019-05-30       Impact factor: 4.946

Review 5.  Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship.

Authors:  Ngozi R Monu; Alan B Frey
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

6.  New principles of cancer therapy give new hope for oncological patients.

Authors:  M Bernadic; R Duchon; R Aziri; B Mladosievicova
Journal:  Bratisl Lek Listy       Date:  2019       Impact factor: 1.278

Review 7.  New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.

Authors:  Peter E Westerweel; Peter A W Te Boekhorst; Mark-David Levin; Jan J Cornelissen
Journal:  Front Oncol       Date:  2019-08-06       Impact factor: 6.244

Review 8.  Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.

Authors:  Xiangfeng Shen; Lihong Zhang; Jicheng Li; Yulin Li; Yishu Wang; Zhi-Xiang Xu
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 9.  MicroRNAs and lncRNAs-A New Layer of Myeloid-Derived Suppressor Cells Regulation.

Authors:  Elham Safarzadeh; Zahra Asadzadeh; Sahar Safaei; Arash Hatefi; Afshin Derakhshani; Francesco Giovannelli; Oronzo Brunetti; Nicola Silvestris; Behzad Baradaran
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  3 in total

1.  Myeloid-Derived Suppressor Cells (MDSCs) in Haematology.

Authors:  Nikoleta Bizymi; Helen A Papadaki
Journal:  J Clin Med       Date:  2021-12-30       Impact factor: 4.241

Review 2.  TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.

Authors:  Hui Qiu; Zhiying Shao; Xin Wen; Jinghua Jiang; Qinggong Ma; Yan Wang; Long Huang; Xin Ding; Longzhen Zhang
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

3.  Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor.

Authors:  Yinan Li; Kailiang Qiao; Xiaoyun Zhang; Haoyang Liu; Heng Zhang; Zhiyang Li; Yanrong Liu; Tao Sun
Journal:  iScience       Date:  2021-11-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.